Research output: Chapter in Book/Report/Conference proceedingChapter


Ranolazine is a novel anti-anginal agent with a “non-haemodynamic” mechanism of action. It is effective as adjunctive therapy in patients with chronic stable angina whose symptoms are not controlled by conventional treatment. The clinical development program of ranolazine has shown that the drug improves exercise performance, reduces angina attacks and hence the use of sublingual nitrates, compared to placebo. Ranolazine is well tolerated with neutral effect on cardiovascular haemodynamics. Besides its role in chronic stable angina, ranolazine may be useful in other cardiovascular conditions in the future. This chapter will focus on the mechanism of action of ranolazine and briefly review current evidence supporting its role as a suitable treatment for stable angina pectoris.

Original languageEnglish
Title of host publicationPharmacological Treatment of Chronic Stable Angina Pectoris
PublisherSpringer International Publishing
Number of pages16
ISBN (Print)9783319173320, 9783319173313
Publication statusPublished - Jan 1 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Ranolazine'. Together they form a unique fingerprint.

  • Cite this

    Rosano, G. M. C., Vitale, C., & Volterrani, M. (2015). Ranolazine. In Pharmacological Treatment of Chronic Stable Angina Pectoris (pp. 173-188). Springer International Publishing. https://doi.org/10.1007/978-3-319-17332-0_9